Response to "COVID-19: room for treating T cell exhaustion?"
- PMID: 32539816
- PMCID: PMC7295579
- DOI: 10.1186/s13054-020-03068-1
Response to "COVID-19: room for treating T cell exhaustion?"
Conflict of interest statement
A.D. was supported by the National Institutes for Health grant K23GM129660.
R.H. has received no direct financial support, nor does he or his family hold patents or equity interest in any biotech or pharmaceutical company. He has received laboratory research support from the Bristol-Myers Squibb, GlaxoSmithKline, and RevImmune; has served as a paid consultant to the Bristol-Myers Squibb and GlaxoSmithKline; and has received grant support from the US NIH and US Public Health Service for research investigations of sepsis.
E.K. has an equity interest in Attune Medical.
Comment on
-
COVID-19: room for treating T cell exhaustion?Crit Care. 2020 May 15;24(1):229. doi: 10.1186/s13054-020-02960-0. Crit Care. 2020. PMID: 32414395 Free PMC article. No abstract available.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources